Clinical Research Directory
Browse clinical research sites, groups, and studies.
Real-world Study on the Prevention of Neutropenia After Tumor Treatment With Mecapegfilgrastim Injection
Sponsor: Hebei Medical University Fourth Hospital
Summary
This study is a multicenter, observational real-world study, aiming to observe and evaluate the efficacy and safety of prophylactic application of Mecapegfilgrastim Injection in tumor patients after radiotherapy/chemotherapy/immunotherapy in the real world to prevent neutropenia.The subjects who met the inclusion criteria of the protocol were defined as those who needed radiotherapy/chemotherapy/immunotherapy after being diagnosed with solid malignant tumors. The researchers believed that the subjects needed to use Mecapegfilgrastim Injection for primary/secondary prevention after receiving tumor treatment.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
200
Start Date
2025-06-18
Completion Date
2027-06-30
Last Updated
2026-02-25
Healthy Volunteers
No
Conditions
Interventions
Mecapegfilgrastim Injection
Use it 24 hours after the end of each treatment cycle at a fixed dose of 6 mg or 100μg/kg each time
Locations (1)
HebeiMuFH
Shijiazhuang, Hebei, China